Drug delivery to the retina: Challenges and opportunities

Expert Opinion on Biological Therapy

Volumn 3, Issue 1, 2003, Pages 45-56

  Duvvuri, Sridhar ^a   Majumdar, Soumyajit ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Blood retinal barrier; Carrier mediated transport; Drug delivery; Ocular bioavailability; Retina; Retinal pigmented epithelium; Transporters

Indexed keywords

4 AMINOBUTYRIC ACID; ACICLOVIR; ADENOSINE; AMINO ACID; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; CEFALEXIN; CEFAZOLIN; CEFTAZIDIME; CIDOFOVIR; DACARBAZINE; EYE DROPS; FOLIC ACID; FOSCARNET; FOSCARNET SODIUM; GANCICLOVIR; GENTAMICIN; GLUTAMINE; GLYCINE; MONOCARBOXYLATE TRANSPORTER; PEPTIDE; PRODRUG; PROLINE; TAURINE; TILISOLOL; TRYPTOPHAN; VERAPAMIL;

BLOOD RETINA BARRIER; DEVICE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RELEASE; IMPLANT; MEMBRANE PERMEABILITY; POSTERIOR EYE CHAMBER; RETINA; REVIEW; RISK BENEFIT ANALYSIS; VITREOUS BODY;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; MEMBRANE TRANSPORT PROTEINS; PRODRUGS; RETINA;

EID: 0037319276     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.1.45     Document Type: Review

References (93)

1. RIZZOLO LJ: Polarity and the development of the outer blood-retinal barrier. Histol. Histopathol. (1997) 12:1057-1067.
2. MARMOR MF: Structure, function and disease of the retinal pigment epithelium, in: The Retinal Pigment Epithelium. Wolfensberger TJ, Marmor MF (Eds.) Oxford University Press. New York, USA (1998):3-9.
3. CUNHA-VAZ JG: The blood-retinal barriers. Doc. Ophthalmol. (1976) 41:287-327.
4. AUKUNURU JV, SUNKARA G, BANDI N, THORESON WB, KOMPELLA UB: Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor. Pharm. Res. (2001) 18:565-572.
5. KENNEDY BG, MANJINI NJ: Native and Cultured Human RPE Express P-glycoprotein. ARVO Annual Meeting, 2002. (2002).
6. HOLASH JA, STEWART PA: The relationship of astrocyte-like cells to the vessels that contribute to the blood-ocular barriers. Brain Res. (1993) 629:218-224.
7. GREENWOOD J: Characterization of a rat retinal endothelial cell culture and the expression of P-glycoprotein in brain and retinal endothelium in vitro. J. Neuroimmunol. (1992) 39:123-132.
8. MILLAY RH, KLEIN ML, SHULTS WT, DAHLBORG SA, NEUWELT EA: Maculopathy associated with combination chemotherapy and osmotic opening of the blood-brain barrier. Am. J. Ophthalmol. (1986) 102:626-632.
9. FRANK JA, DWYER AJ, GIRTON M et al.: Opening of blood-ocular barrier demonstrated by contrast-enhanced MR imaging. J. Comput. Assist. Tomogr. (1986) 10:912-916.
10. MACHA S, MITRA AK: Ocular disposition of ganciclovir and its monoester prodrugs following intravitreal administration using microdialysis. Drug Metab. Dispos. (2002) 30:670-675.
11. COSTABILE BS: Treatment of cytomegalovirus retinitis with intraocular implants. AORN J. (1998) 67:356-360, 362-365,368; quiz 369-372.
12. HUGHES PM, MITRA AK: Overview of Ocular Drug Delivery, in: Drug Delivery Systems, Mitra AK (Ed.), Marcell Dekker, Inc., New York, USA (1993).
13. ACHEAMPONG AA, SHACKLETON M, JOHN B et al.: Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab. Dispos. (2002) 30:421-429.
14. SIEGNER SW, GIOVANONI RL, ERICKSON KA, NETLAND PA: Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits. J. Ocul. Pharmacol. Ther. (1998) 14:159-168.
15. MACHA S, MITRA AK: Ocular pharmacokinetics of cephalosporins using microdialysis. J. Ocul. Pharmacol. Ther. (2001) 17:485-498.
16. BEN-NUN J, JOYCE DA, COOPER RL, CRINGLE SJ, CONSTABLE IJ: Pharmacokinetics of intravitreal injection. Assessment of a gentamicin model by ocular dialysis. Invest. Ophthalmol. Vis. Sci. (1989) 30:1055-1061.
17. LOPEZ-CORTES LF, PASTOR-RAMOS MT, RUIZ-VALDERAS R et al.: Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits. Invest. Ophthalmol. Vis. Sci. (2001) 42:1024-1028.
18. CUNDY KC, LYNCH G, SHAW JP, HITCHCOCK MJ, LEE WA: Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits. Curr. Eye Res. (1996) 15:569-576.
19. HUGHES PM, KRISHNAMOORTHY R, MITRA AK: Vitreous disposition of two acycloguanosine antivirals in the albino and pigmented rabbit models: a novel ocular microdialysis technique. J. Ocul. Pharmacol. Ther. (1996) 12:209-224.
20. WAGA J, NILSSON-EHLE I, LJUNGBERG B et al.: Microdialysis for pharmacokinetic studies of ceftazidime in rabbit vitreous. J. Ocul. Pharmacol. Ther. (1999) 15:455-463.
21. MACHA S, MITRA AK: Ocular pharmacokinetics in rabbits using a novel dual probe microdialysis technique. Exp Eye Res. (2001) 72:289-299.
22. LALEZARI JP, FRIEDBERG DN, BISSETT J et al.: High dose oral ganciclovir treatment for cytomegalovirus retinitis. J. Clin. Virol. (2002) 24:67-77.
23. LOPEZ-CORTES LF, RUIZ-VALDERAS R, LUCERO-MUNOZ MJ et al.: Intravitreal, retinal, and central nervous system foscarnet concentrations after rapid intravenous administration to rabbits. Antimicrob. Agents Chemother. (2000) 44:756-759.
24. HENDERLY DE, FREEMAN WR, CAUSEY DM, RAO NA: Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology (1987) 94:425-434.
25. JABS DA, NEWMAN C, DE BUSTROS S, POLK BF: Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology (1987) 94:824-830.
26. BAUM J, PEYMAN GA, BARZA M: Intravitreal administration of antibiotic in the treatment of bacterial endophthalmitis. III. Consensus. Surv. Ophthalmol. (1982) 26:204-206.
27. DIAMOND JG: Intraocular management of endophthalmitis. A systematic approach. Arch. Ophthalmol. (1981) 99:96-99.
28. MARTIN DF, SIERRA-MADERO J, WALMSLEY S et al.: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N. Engl. J. Med. (2002) 346:1119-1126.
29. STONE TW, JAFFE GJ: Reversible bull's-eye maculopathy associated with intravitreal fomivirsen therapy for cytomegalovirus retinitis. Am. J. Ophthalmol. (2000) 130:242-243.
30. BAUDOUIN C, CHASSAIN C, CAUJOLLE C, GASTAUD P: Treatment of cytomegalovirus retinitis in AIDS patients using intravitreal injections of highly concentrated ganciclovir. Ophthalmologica (1996) 210:329-335.
31. CANTRILL HL, HENRY K, MELROE NH et al.: Treatment of cytomegalovirus retinitis with intravitreal ganciclovir. Long-term results. Ophthalmology (1989) 96:367-374.
32. VELOSO AA JR, ZHU Q, HERRERO-VANRELL R, REFOJO MF: Ganciclovir-loaded polymer microspheres in rabbit eyes inoculated with human cytomegalovirus. Invest. Ophthalmol. Vis. Sci. (1997) 38:665-675.
33. PEYMAN GA, KHOOBEHI B, TAWAKOL M et al.: Intravitreal injection of liposome-encapsulated ganciclovir in a rabbit model. Retina (1987) 7:227-229.
34. DIAZ-LLOPIS M, MARTOS MJ, ESPANA E et al.: Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients. Eperimental toxicity and pharmacokinetics, and clinical trial. Doc. Ophthalmol. (1992) 82:297-305.
35. HERRERO-VANRELL R, REFOJO MF: Biodegradable microspheres for vitreoretinal drug delivery. Adv. Drug Deliv. Rev. (2001) 52:5-16.
36. MAURICE D: Review: practical issues in intravitreal drug delivery. J. Ocul. Pharmacol. Ther. (2001) 17:393-401.
37. SAKURAI E, MATSUDA Y, OZEKI H et al.: Scleral plug of biodegradable polymers containing ganciclovir for experimental cytomegalovirus retinitis. Invest. Ophthalmol. Vis. Sci. (2001) 42:2043-2048.
38. UNLU N, ROBINSON JR: Scleral permeability to hydrocortisone and mannitol in the albino rabbit eye. J. Ocul. Pharmacol. Ther. (1998) 14:273-281.
39. YASUKAWA T, KIMURA H, TABATA Y, OGURA Y: Biodegradable scleral plugs for vitreoretinal drug delivery. Adv. Drug Deliv. Rev. (2001) 52:25-36.
40. SASAKI H, ICHIKAWA M, KAWAKAMI S et al.: In situ ocular absorption of tilisolol through ocular membranes in albino rabbits. J. Pharm. Sci. (1996) 85:940-943.
41. KALSI GS, SILVER HK, ROOTMAN J: Ocular pharmacokinetics of dacarbazine following subconjunctival versus intravenous administration in the rabbit. Can. J. Ophthalmol. (1991) 26:247-251.
42. HATEFI A, AMSDEN B: Biodegradable injectable in situ forming drug delivery systems. J. Control Release (2002) 80:9-28.
43. GEROSKI DH, EDELHAUSER HF: Transscleral drug delivery for posterior segment disease. Adv. Drug. Deliv. Rev. (2001) 52:37-48.
44. EINMAHL S, SAVOLDELLI M, D'HERMIES F et al.: Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye. Invest. Ophthalmol. Vis. Sci. (2002) 43:1533-1539.
45. ZIGNANI M, EINMAHL S, BAEYENS V et al.: A poly(ortho ester) designed for combined ocular delivery of dexamethasone sodium phosphate and 5-fluorouracil: subconjunctival tolerance and in vitro release. Eur. J. Pharm. Biopharm. (2000) 50:251-255.
46. SMITH TJ, ASHTON P: Sustained-release subconjunctival 5-fluorouracil. Ophthalmic Surg. Lasers (1996) 27:763-767.
47. LEE VH: Membrane transporters. Eur. J. Pharm. Sci. (2000) 11(Suppl. 2):S41-S50.
48. BERGER UV, HEDIGER MA: Distribution of peptide transporter PEPT2 mRNA in the rat nervous system. Anat. Embryol. (Berl.) (1999) 199:439-449.
49. BAN Y, RIZZOLO LJ: Regulation of glucose transporters during development of the retinal pigment epithelium. Brain Res. Dev. Brain Res. (2000) 121:89-95.
50. POW DV: Amino acids and their transporters in the retina. Neurochem. Int. (2001) 38:463-484.
51. WILLIAMS EF, EZEONU I, DUTT K: Nucleoside transport sites in a cultured human retinal cell line established by SV-40 T antigen gene. Curr. Eye Res. (1994) 13:109-118.
52. SMITH QR: Drug delivery to brain and the role of carrier-mediated transport. Adv. Exp. Med. Biol. (1993) 331:83-93.
53. CHEN L, WRIGHT LR, CHEN CH et al.: Molecular transporters for peptides: delivery of a cardioprotective epsilonPKC agonist peptide into cells and intact ischemic heart using a transport system, R(7). Chem. Biol. (2001) 8:1123-1129.
54. PUTNAM WS, PAN L, TSUTSUI K, TAKAHASHI L, BENET LZ: Comparison of bidirectional cephalexin transport across MDCK and caco-2 cell monolayers: interactions with peptide transporters. Pharm. Res. (2002) 19:27-33.
55. GRONEBERG DA, DORING F, THEIS S et al.: Peptide transport in the mammary gland: expression and distribution of PEPT2 mRNA and protein. Am. J. Physiol. Endocrinol. Metab. (2002) 282:E1172-1179.
56. KRAMER W, DECHENT C, GIRBIG F, GUTJAHR U, NEUBAUER H: Intestinal uptake of dipeptides and beta-lactam antibiotics. I. The intestinal uptake system for dipeptides and beta-lactam antibiotics is not part of a brush border membrane peptidase. Biochim. Biophys. Acta. (1990) 1030:41-49.
57. DANIEL H, ADIBI SA: Transport of betalactam antibiotics in kidney brush border membrane. Determinants of their affinity for the oligopeptide/H+ symporter. J. Clin. Invest. (1993) 92:2215-2223.
58. DIECK ST, HEUER H, EHRCHEN J, OTTO C, BAUER K.: The peptide transporter PepT2 is expressed in rat brain and mediates the accumulation of the fluorescent dipeptide derivative beta-Ala-Lys-Nepsilon-AMCA in astrocytes. Glia (1999) 25:10-20.
59. DORING F, MARTINI C, WALTER J, DANIEL H: Importance of a small N-terminal region in mammalian peptide transporters for substrate affinity and function. J. Membr. Biol. (2002) 186:55-62.
60. TERADA T, SAITO H, MUKAI M, INUI KI: Identification of the histidine residues involved in substrate recognition by a rat H+/peptide cotransporter, PEPT1. FEBS Lett. (1996) 394:196-200.
61. FEI YJ, LIU W, PRASAD PD et al.: Identification of the histidyl residue obligatory for the catalytic activity of the human H+/peptide cotransporters PEPT1 and PEPT2. Biochemistry (1997) 36:452-460.
62. KRAMER W, DURCKHEIMER W, GIRBIG F et al.: Influence of amino acid side-chain modification on the uptake system for beta-lactam antibiotics and dipeptides from rabbit small intestine. Biochim. Biophys. Acta (1990) 1028:174-182.
63. MEREDITH D, TEMPLE CS, GUHA N et al.: Modified amino acids and peptides as substrates for the intestinal peptide transporter PepT1. Eur. J. Biochem. (2000) 267:3723-3728.
64. YANG C, TIRUCHERAI GS, MITRA AK.: Prodrug based optimal drug delivery via membrane transporter/receptor. Expert. Opin. Biol. Ther. (2001) 1:159-175.
65. HAN H, DE VRUEH RL, RHIE JK et al.: 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm. Res. (1998) 15:1154-1159.
66. PESCOVITZ MD, RABKIN J, MERION RM et al.: Valganciclovir results in improved oral absorption of ganciclovir in the liver transplant recipients. Antimicrob. Agents Chemother. (200) 44:2811-2815.
67. ATLURI H, ANAND BS, PATEL J, MITRA AK: Carrier mediated transport of a dipeptide across blood retinal barrier following systemic administration. AAPS Annual meeting (2002).
68. MUNCK LK, GRONDAHL ML, THORBOLL JE, SKADHAUGE E, MUNCK BG: Transport of neutral, cationic and anionic amino acids by systems B, b(o,+), X(AG), and ASC in swine small intestine. Comp. Biochem. Physiol. A Mol. Integr. Physiol. (2000) 126:527-537.
69. KILBERG MS, STEVENS BR, NOVAK DA: Recent advances in mammalian amino acid transport. Ann. Rev. Nutr. (1993) 13:137-165.
70. KANAI Y, SEGAWA H, CHAIROUNGDUA A et al.: Amino acid transporters: molecular structure and physiological roles. Nephrol. Dial. Transplant. (2000) 15:9-10.
71. FUKASAWA Y, SEGAWA H, KIM JY et al.: Identification and characterization of a Na(+)-independent neutral amino acid transporter that associates with the 4F2 heavy chain and exhibits substrate selectivity for small neutral D- and L-amino acids. J. Biol. Chem. (2000) 275:9690-9698.
72. YANG C, MITRA AK: Nasal absorption of tyrosine-linked model compounds. J. Pharm. Sci. (2001) 90:340-347.
73. HARGREAVES KM, PARDRIDGE WM: Neutral amino acid transport at the human blood-brain barrier. J. Biol. Chem. (1988) 263:19392-19397.
74. ALM A, TORNQUIST P: Lactate transport through the blood-retinal and the blood-brain barrier in rats. Ophthalmic Res. (1985) 17:181-184.
75. TAMAI I, SAI Y, ONO A et al.: Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1. J. Pharm. Pharmacol. (1999) 51:1113-1121.
76. NORD EP, WRIGHT SH, KIPPEN I, WRIGHT EM: Specificity of the Na+-dependent monocarboxylic acid transport pathway in rabbit renal brush border membranes. J. Membr. Biol. (1983) 72:213-221.
77. KANG YS, TERASAKI T, TSUJI A: Acidic drug transport in vivo through the blood-brain barrier. A role of the transport carrier for monocarboxylic acids. J. Pharmacobiodyn. (1990) 13:158-163.
78. TERASAKI T, TAKAKUWA S, MORITANI S, TSUJI A: Transport of monocarboxylic acids at the blood-brain barrier: studies with monolayers of primary cultured bovine brain capillary endothelial cells. J. Pharmacol. Exp. Ther. (1991) 258:932-937.
79. GERHART DZ, LEINO RL, DREWES LR: Distribution of monocarboxylate transporters MCT1 and MCT2 in rat retina. Neuroscience (1999) 92:367-375.
80. BERGERSEN L, JOHANNSSON E, VERUKI ML et al.: Cellular and subcellular expression of monocarboxylate transporters in the pigment epithelium and retina of the rat. Neuroscience (1999) 90:319-331.
81. HALESTRAP AP, PRICE NT: The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem. J. (1999) 343(Pt 2):281-299.
82. TAMAI I, TAKANAGA H, MAEDA H et al. Proton-cotransport of pravastatin across intestinal brush-border membrane. Pharm. Res. (1995) 12:1727-1732.
83. TAKANAGA H, TAMAI I, TSUJI A: pH-dependent and carrier-mediated transport of salicylic acid across Caco-2 cells. J. Pharm. Pharmacol. (1994) 46:567-570.
84. TAKANAGA H, MAEDA H, YABUUCHI H et al.: Nicotinic acid transport mediated by pH-dependent anion antiporter and proton cotransporter in rabbit intestinal brush-border membrane. J. Pharm. Pharmacol. (1996) 48:1073-1077.
85. HOSOYA K, KONDO T, TOMI M et al.: MCT1-mediated transport of L-lactic acid at the inner blood-retinal barrier: a possible route for delivery of monocarboxylic acid drugs to the retina. Pharm. Res. (2001) 18:1669-1676.
86. HORIBE Y, HOSOYA K, KIM KJ, LEE VH: Carrier-mediated transport of monocarboxylate drugs in the pigmented rabbit conjunctiva. Invest. Ophthalmol. Vis. Sci. (1998) 39:1436-1443.
87. YOON H, FANELLI A, GROLLMAN EF, PHILP NJ: Identification of a unique monocarboxylate transporter (MCT3) in retinal pigment epithelium. Biochem. Biophys. Res. Commun. (1997) 234:90-94.
88. CHANCY CD, KEKUDA R, HUANG W et al.: Expression and differential polarization of the reduced-folate transporter-1 and the folate receptor alpha in mammalian retinal pigment epithelium. J. Biol. Chem. (2000) 275:20676-20684.
89. SIROTNAK FM, TOLNER B: Carrier-mediated membrane transport of folates in mammalian cells. Ann. Rev. Nutr. (1999) 19:91-122.
90. ANTONY AC: The biological chemistry of folate receptors. Blood (1992) 79:2807-2820.
91. REDDY JA, LOW PS: Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. J. Control. Release (2000) 64:27-37.
92. SMITH SB, KEKUDA R, GU X et al.: Expression of folate receptor alpha in the mammalian retinol pigmented epithelium and retina. Invest. Ophthalmol. Vis. Sci. (1999) 40:840-848.
93. SUDIMACK J, LEE RJ: Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. (2000) 41:147-162.